Drawing on a deep understanding of the underlying causes of some of the most challenging diseases, Ichnos Sciences is pursuing truly disease-centric therapies in oncology and autoimmune disease. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.
Compound | Target | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
---|---|---|---|---|---|---|
ISB 1342 | CD38 x CD3 BEAT® bispecific antibody |
|||||
ISB 1908 | CD38 x CD3 BEAT® bispecific antibody | 2H 2020 | ||||
ISB 1909 | BEAT® T-cell engager | 1H 2021 | ||||
ISB 1442 | CD38 x CD47 BEAT® bispecific antibody | 2H 2020 | ||||
ISB 1302 | HER2 x CD3 BEAT® bispecific antibody |
|||||
ISC XXXXX | HPK1 inhibitor small molecule | 2H 2020 |
Compound | Target | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
---|---|---|---|---|---|---|
ISB 830† | OX40 antagonist monoclonal antibody | |||||
ISB 880 | IL-1RAP antagonist monoclonal antibody | 2H 2020 |
Compound | Target | Preclinical | IND-Enabling | phase 1 | phase 2 | phase 3 |
---|---|---|---|---|---|---|
ISC 17536* | TPRA1 antagonist small molecule |
†A US IND to conduct studies of ISB 830 in additional indications, including Rheumatoid Arthritis, is active. Options for future development, including potentially partnering with other companies, are under consideration.
*Ichnos Sciences will complete preclinical and clinical work required to start a randomized Phase 2b study of ISC 17536 and plans to out-license the compound to enable greater focus on oncology and autoimmune disease.
Note: Assets that were previously identified as GBR and GRC are now identified as ISB (for biologics) and ISC (for small molecules), respectively.
The links above are provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.